Business & Economy · 46 views
OKYO Pharma appoints Leerink Partners as sales agent for ATM equity offering
Business & Economy 
Story intelligence
Coverage Single outlet Single-outlet story
Views 46 Community interest
Brief read Under 1 min brief 28 words
Summary
OKYO Pharma Ltd (NASDAQ:OKYO) a clinical-stage biopharmaceutical company focused on therapies for neuropathic corneal pain and inflammatory eye diseases, announced that it has transitioned its At-The-Market (ATM) equity
AI summaries can be wrong sometimes—always verify important details using the source article.
How AI & Automation are usedCoverage Context
Part of ATM coverage 16 tracked stories
More from Business & Economy
Continue reading recent Business & Economy coverage
- Why a longtime skeptic of Palantir’s stock is finally saying it’s time to buyContinue reading
- Nvidia, Oracle, CoreWeave and other AI stocks sink on OpenAI revenue reportContinue reading
- I’m a 68-year-old widow and give money to my two adult children. Am I putting my retirement at risk?Continue reading
- Judge Extends Pause on Trump’s Ban Against CNN, MS NOW and PoliticoContinue reading
Support HappeningNow
Independent AI-powered news analysis is reader-supported. Your contribution helps cover infrastructure, summaries, and continued platform development.
Support HappeningNow